tailieunhanh - AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC). Cetuximab is currently the only EGFR-targeting agent approved by the FDA for treatment of HNC; however, intrinsic and acquired resistance to cetuximab is a major problem in the clinic. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN